ELAHERE™ (mirvetuximab soravtansine-gynx), FDA Approved for Platinum-Resistant Ovarian Cancer, Available at Biologics by McKesson

CARY, N.C., Dec. 12, 2022 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates (ADCs), as the sole specialty pharmacy provider for ELAHERE™ (mirvetuximab soravtansine-gynx) for the treatment of adult patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.

ELAHERE™ was approved by the U.S. Food and Drug Administration (FDA) on November 14, 2022, under the FDA's accelerated approval program based on objective response rate and duration of response data from the pivotal SORAYA trial. The SORAYA trial was a single-arm study in 106 patients with platinum-resistant ovarian cancer whose tumors expressed high levels of FRα and who had been treated with one to three prior systemic treatment regimens – at least one of which included Avastin® (bevacizumab). The primary endpoint was confirmed overall response rate (ORR) as assessed by investigators, and the key secondary endpoint was duration of response (DOR). Per the label, ELAHERE™ demonstrated an ORR by investigators of 31.7% (95% confidence interval [CI]: 22.9, 41.6), including five complete responses (CRs). The median DOR was 6.9 months (95% CI: 5.6, 9.7) as assessed by investigators. The safety of ELAHERE™ has been evaluated in a pooled analysis from three studies among a total of 464 patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who received at least one dose of ELAHERE™ (6 mg/kg adjusted ideal body weight (AIBW) administered intravenously once every 3 weeks).

“We are honored to support this significant therapy approval for platinum-resistant ovarian patients and are thrilled to be selected by ImmunoGen as the sole specialty pharmacy for ELAHERE™,” said Ela Lourido, vice president, Biopharma Services, Biologics by McKesson.

Biologics specialty pharmacy is committed to and recognized for its level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients.

For more information about the role of FRα in ovarian cancer, click here. For more information about ELAHERE™, including full prescribing information, including a boxed warning, please click here.

ELAHERE™ is a trademark of ImmunoGen, Inc.

About Biologics by McKesson

Biologics by McKesson is an independent specialty pharmacy with more than 25 years of experience connecting patients to life-changing medications in oncology and other rare and complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As a business within McKesson Corporation, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers, and biopharma, so together, they can deliver better care and outcomes for every patient.